EXOZ
Income statement / Annual
Last year (2024), eXoZymes Inc.'s total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2024, eXoZymes Inc.'s net income was -$5.86 M.
See eXoZymes Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
| Operating Revenue |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Cost of Revenue |
$267.38 K
|
$0.00
|
$147.75 K
|
$59.41 K
|
| Gross Profit |
-$267.38 K
|
$0.00
|
-$147.75 K
|
-$59.41 K
|
| Gross Profit Ratio |
0
|
0
|
0
|
0
|
| Research and Development Expenses |
$1.87 M
|
$527.48 K
|
$348.08 K
|
$454.45 K
|
| General & Administrative Expenses |
$0.00
|
$1.34 M
|
$0.00
|
$0.00
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$3.80 M
|
$1.34 M
|
$836.83 K
|
$778.99 K
|
| Other Expenses |
$0.00
|
-$70.07 K
|
$0.00
|
$0.00
|
| Operating Expenses |
$5.66 M
|
$1.80 M
|
$1.18 M
|
$1.23 M
|
| Cost And Expenses |
$5.93 M
|
$1.80 M
|
$1.33 M
|
$1.29 M
|
| Interest Income |
$77.61 K
|
$100.00
|
$98.00
|
$0.00
|
| Interest Expense |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Depreciation & Amortization |
$267.38 K
|
$196.94 K
|
$147.75 K
|
$59.41 K
|
| EBITDA |
-$5.59 M |
-$1.60 M |
-$1.18 M |
-$1.15 M |
| EBITDA Ratio |
0
|
0
|
0
|
0
|
| Operating Income Ratio |
0
|
0
|
0
|
0
|
| Total Other Income/Expenses Net |
$70.77 K
|
-$199.90 K
|
$98.00
|
$83.74 K
|
| Income Before Tax |
-$5.86 M
|
-$2.00 M
|
-$1.33 M
|
-$1.21 M
|
| Income Before Tax Ratio |
0
|
0
|
0
|
0
|
| Income Tax Expense |
$0.00
|
$42.27 K
|
$63.56 K
|
$0.00
|
| Net Income |
-$5.86 M
|
-$2.04 M
|
-$1.40 M
|
-$1.21 M
|
| Net Income Ratio |
0
|
0
|
0
|
0
|
| EPS |
-0.72 |
-0.25 |
-0.17 |
-0.15 |
| EPS Diluted |
-0.72 |
-0.25 |
-0.17 |
-0.15 |
| Weighted Average Shares Out |
$8.13 M
|
$8.13 M
|
$8.13 M
|
$8.13 M
|
| Weighted Average Shares Out Diluted |
$8.13 M
|
$8.13 M
|
$8.13 M
|
$8.13 M
|
| Link |
|
|
|
|
